Jpmorgan Chase & CO Cytokinetics Inc Transaction History

Jpmorgan Chase & CO

$1.23 Trillion
Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Cytokinetics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,618,402 shares of CYTK stock, worth $63.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,618,402

Previous 1,234,917 31.05%

Holding current value

$63.9 Million

Previous $65.2 Million 16.76%

% of portfolio

0.01%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$46.36 - $58.62 $17.8 Million - $22.5 Million	383,485 Added 31.05%	1,618,402 $76.1 Million
Q3 2024 Dec 26, 2024	BUY	$51.22 - $60.16 $6.3 Million - $7.4 Million	122,974 Added 11.06%	1,234,917 $65.2 Million
Q3 2024 Nov 08, 2024	BUY	$51.22 - $60.16 $6.3 Million - $7.4 Million	122,974 Added 11.06%	1,234,917 $65.2 Million
Q2 2024 Dec 26, 2024	SELL	$47.86 - $75.05 $5.89 Million - $9.23 Million	-122,974 Reduced 9.96%	1,111,943 $60.2 Million
Q2 2024 Aug 12, 2024	BUY	$47.86 - $75.05 $20.3 Million - $31.8 Million	423,839 Added 61.6%	1,111,943 $60.2 Million
Q1 2024 Dec 26, 2024	SELL	$63.75 - $108.06 $34.9 Million - $59.1 Million	-546,813 Reduced 44.28%	688,104 $48.2 Million
Q1 2024 May 10, 2024	BUY	$63.75 - $108.06 $25.7 Million - $43.6 Million	403,704 Added 141.95%	688,104 $48.2 Million
Q4 2023 Dec 26, 2024	SELL	$26.88 - $83.49 $25.5 Million - $79.4 Million	-950,517 Reduced 76.97%	284,400 $23.7 Million
Q4 2023 Feb 12, 2024	SELL	$26.88 - $83.49 $2.73 Million - $8.49 Million	-101,701 Reduced 26.34%	284,400 $23.7 Million
Q3 2023 Nov 14, 2023	BUY	$29.46 - $36.61 $326,888 - $406,224	11,096 Added 2.96%	386,101 $11.4 Million
Q2 2023 Aug 11, 2023	BUY	$32.62 - $40.75 $617,659 - $771,601	18,935 Added 5.32%	375,005 $12.2 Million
Q1 2023 May 18, 2023	BUY	$33.36 - $45.71 $3.86 Million - $5.29 Million	115,805 Added 48.2%	356,070 $12.5 Million
Q1 2023 May 11, 2023	SELL	$33.36 - $45.71 $2.37 Million - $3.24 Million	-70,933 Reduced 22.79%	240,265 $8.45 Million
Q4 2022 Feb 13, 2023	BUY	$35.77 - $51.11 $2.84 Million - $4.06 Million	79,423 Added 34.27%	311,198 $14.3 Million
Q3 2022 Nov 14, 2022	SELL	$38.54 - $54.52 $55,420 - $78,399	-1,438 Reduced 0.62%	231,775 $11.2 Million
Q2 2022 Aug 11, 2022	BUY	$33.93 - $48.92 $5.71 Million - $8.23 Million	168,187 Added 258.65%	233,213 $9.16 Million
Q1 2022 May 11, 2022	BUY	$29.74 - $46.0 $336,032 - $519,754	11,299 Added 21.03%	65,026 $2.39 Million
Q4 2021 Feb 10, 2022	BUY	$34.35 - $46.38 $638,291 - $861,833	18,582 Added 52.87%	53,727 $2.45 Million
Q3 2021 Nov 12, 2021	BUY	$18.54 - $35.74 $651,588 - $1.26 Million	35,145 New	35,145 $1.26 Million

Others Institutions Holding CYTK

# of Institutions

401

Shares Held

115M

Call Options Held

3.46M

Put Options Held

1.86M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $3.72B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Cytokinetics Inc Transaction History